<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>News Article</title>

    <!-- bootstrap css cdn link -->

    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Poppins:wght@300;400;500;600;700;800&display=swap"
        rel="stylesheet">

    <!-- CSS only -->
    <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.0.1/dist/css/bootstrap.min.css" rel="stylesheet"
        integrity="sha384-+0n0xVW2eSR5OomGNYDnhzAbDsOXxcvSN1TPprVMTNDbiYZCxYbOOl7+AMvyTG2x" crossorigin="anonymous">

    <!-- custom css stylesheet -->
    <link rel="stylesheet" href="./../assets/css/connect.css">
    <link rel="stylesheet" href="./../assets/css/news_article.css">
    <link rel="stylesheet" href="../assets/css/navbar.css">
    <link rel="stylesheet" href="../assets/css/footer-mobile.css">
    <link rel="stylesheet" href="./../assets/css/animate_footer.css">
</head>

<body>

    <!-- scroll up btn -->
    <div class="scroll-up hide-btn">
        <span class="scroll-up-btn">^</span>
    </div>

    <!-- header navabr -->
    <section class="navbar">
        <div class="navbar-container">
            <a href="../home.html" class="nav_main_icon">
                <img src="../assets/img/home/Menu/LOGO_.png" alt="taiba">
            </a>
            <div class="nav-btn">
                <span class="nav_btn_line line-1"></span>
                <span class="nav_btn_line line-2"></span>
                <span class="nav_btn_line line-3"></span>
            </div>
        </div>
    </section>

    <!-- navbar expended -->
    <nav class="nav">
        <div class="nav-container">
            <div class="nav-outer-1">
                <div class="nav-follow-container">
                    <span>Follow us</span>
                    <div class="nav-social-container">
                        <a href="#" class="nav-social-link"><img src="../assets/img/home/footer/LINKEDIN.png"
                                alt="linkedin"></a>
                        <a href="#" class="nav-social-link"><img src="../assets/img/home/footer/TWITTER_.png"
                                alt="twitter"></a>
                        <a href="#" class="nav-social-link"><img src="../assets/img/home/footer/FB_.png"
                                alt="facebook"></a>
                        <a href="#" class="nav-social-link"><img src="../assets/img/home/footer/IG_.png"
                                alt="instagram"></a>
                    </div>
                </div>
                <div class="nav_open_logo">
                    <a href="../home.html" class="nav_main_icon"><img src="../assets/img/accessrare.png"
                            alt="taiba"></a>
                    <div class="nav-close-btn">&Cross;</div>
                </div>
            </div>
            <div class="nav-outer-2">
                <div class="nav-list-1">
                    <div class="nav-item">
                        <a href="../home.html" class="nav-link">Who we are</a>
                        <div class="nav-sub-items">
                            <a href="../home.html" class="nav-sub-link">Our story</a>
                            <!-- <a href="../home.html" class="nav-sub-link">Letter From Our CEO</a> -->
                            <a href="../our-people.html" class="nav-sub-link">Our people</a>
                        </div>
                    </div>
                    <div class="nav-item">
                        <a href="../whatwedo.html" class="nav-link">What we do</a>
                    </div>
                    <div class="nav-item">
                        <a href="../patient-support.html" class="nav-link">Patient support</a>
                    </div>
                    <div class="nav-item">
                        <a href="../aof.html" class="nav-link">Areas of focus</a>
                        <div class="nav-sub-items link-hide">
                            <a href="../aof.html" class="nav-sub-link">Rare diseases in the middle east</a>
                        </div>
                    </div>
                </div>
                <div class="nav-list-2">
                    <div class="nav-item">
                        <a href="../partnerships.html" class="nav-link">Partnership</a>
                        <div class="nav-sub-items link-hide">
                            <a href="../partnerships.html" class="nav-sub-link">Partnering with taiba</a>
                            <a href="../partnerships.html" class="nav-sub-link">Our areas of interest</a>
                            <a href="../partnerships.html" class="nav-sub-link">Partnership forms</a>
                            <!-- <a href="../partnerships.html" class="nav-sub-link">Why Partner with Taiba</a> -->
                        </div>
                    </div>
                    <div class="nav-item">
                        <a href="../news.html" class="nav-link">News</a>
                        <!-- <div class="nav-sub-items link-hide">
                            <a href="../news.html" class="nav-sub-link">Events & Announcements</a>
                        </div> -->
                    </div>
                    <div class="nav-item">
                        <a href="../connect.html" class="nav-link">Connect</a>
                    </div>
                </div>
            </div>
            <div class="nav-outer-3">
                <a href="#" class="visit-btn">Visit taiba healthcare <span>&rarr;</span></a>
            </div>
        </div>
    </nav>

    <section class="main">

        <!-- article meta info start -->
        <div class="article-header">
            <img src="./../assets/img/news/news-article/Alnylam Pharmaceuticals.jpg" class="article-img"
                alt="article image">
            <img src="./../assets/img/news/news-article/NEWS_article_White header.png" alt="overlay"
                class="article-img-overlay">
            <div class="article-heading">
                <div class="date">
                    <p>00/06/2020</p>
                </div>
                <h1 class="heading--1">
                    Alnylam Pharmaceuticals and Taiba Group Partner to Commercialize RNAi
                    Therapeutics in the Gulf States


                </h1>
                <button type="button" class="scroll-btn">Scroll Down</button>
            </div>
        </div>
        <!-- article meta info end -->

        <!-- article content start -->
        <div class="article-text-container">
            <p class="article-text">ZUG, Switzerland & DUBAI, United Arab Emirates--(BUSINESS WIRE)--Alnylam
                Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and taiba Middle East, a
                leading rare disease company based in the United Arab Emirates and covering the Middle East region,
                announced today that they have formed a Distribution Agreement for both ONPATTRO® and GIVLAARI®, the
                first-ever commercialized RNAi therapeutics, as well as another late-stage therapy in development for
                Primary Hyperoxaluria Type 1.</p>
            <p class="article-text">“The cooperation with taiba allows us to address the unmet medical needs of patients
                with rare diseases, particularly where those diseases have a higher regional prevalence. That is why it
                is so important that patients in the Middle East are not disadvantaged when it comes to accessing
                effective treatments,” said Brendan Martin, Vice President and Acting Head of Europe, Middle East &
                Africa, and Canada, Alnylam Pharmaceuticals. “taiba has a regional presence with operations in multiple
                Gulf states, and a proven track record of marketing and distributing medicines for rare diseases. Our
                collaboration marks an important first step in bringing our current and future therapies to those
                patients with urgent medical needs.”</p>
            <p class="article-text">Alnylam Pharmaceuticals and Taiba Group Partner to Commercialize RNAi Therapeutics
                in the Gulf States
                July 08, 2020 07:57 AM Eastern Daylight Time
                ZUG, Switzerland & DUBAI, United Arab Emirates--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:
                ALNY), the leading RNAi therapeutics company, and taiba Middle East, a leading rare disease company
                based in the United Arab Emirates and covering the Middle East region, announced today that they have
                formed a Distribution Agreement for both ONPATTRO® and GIVLAARI®, the first-ever commercialized RNAi
                therapeutics, as well as another late-stage therapy in development for Primary Hyperoxaluria Type 1.

                “We are proud to collaborate with Alnylam in the Gulf states”

                Tweet this
                “The cooperation with taiba allows us to address the unmet medical needs of patients with rare diseases,
                particularly where those diseases have a higher regional prevalence. That is why it is so important that
                patients in the Middle East are not disadvantaged when it comes to accessing effective treatments,” said
                Brendan Martin, Vice President and Acting Head of Europe, Middle East & Africa, and Canada, Alnylam
                Pharmaceuticals. “taiba has a regional presence with operations in multiple Gulf states, and a proven
                track record of marketing and distributing medicines for rare diseases. Our collaboration marks an
                important first step in bringing our current and future therapies to those patients with urgent medical
                needs.”

                “We are proud to collaborate with Alnylam in the Gulf states,” said Saif Al Hasani CEO of the taiba
                Group. “Alnylam’s portfolio of ground-breaking medicines will enhance our rare disease portfolio and
                enable us to offer innovative treatments to patients. Those patients with hATTR amyloidosis and other
                rare diseases deserve to have the earliest possible access to novel new treatments. We look forward to
                making this a reality, beginning with ONPATTRO and GIVLAARI.”</p>
            <p class="article-text">
                The Agreement between Alnylam and taiba will initially cover the Gulf states, including the Kingdom of
                Saudi Arabia, Kuwait, Bahrain, Qatar, Oman and the United Arab Emirates. It includes ONPATTRO, approved
                in the European Union (EU) in August 2018 for the treatment of hATTR amyloidosis in adults with stage 1
                or stage 2 polyneuropathy; GIVLAARI, approved in the EU in March 2020 for the treatment of acute hepatic
                porphyria (AHP); and lumasiran, a late-stage investigational RNAi therapeutic for the treatment of
                Primary Hyperoxaluria Type 1 (PH1).
            </p>
            <p class="article-text">
                “We are pleased to partner with taiba to provide access to ARIKAYCE for appropriate patients in the Gulf
                Cooperation Council region,” said Neil Hughes, General Manager, Head of EMEA, for Insmed. “Taiba’s
                extensive experience in providing access to rare disease therapies in the Middle East makes it an ideal
                partner for Insmed as we expand our reach globally and serve patients with significant unmet needs.”
            </p>
            <h3 class="article-sub-heading">About ONPATTRO® (patisiran)</h3>
            <p class="article-text">
                ONPATTRO is an RNAi therapeutic that was approved in the United States and Canada for the treatment of
                the polyneuropathy of hATTR amyloidosis in adults. ONPATTRO is also approved in the European Union,
                Switzerland and Brazil for the treatment of hATTR amyloidosis in adults with Stage 1 or Stage 2
                polyneuropathy, and in Japan for the treatment of hATTR amyloidosis with polyneuropathy. ONPATTRO is an
                intravenously administered RNAi therapeutic targeting transthyretin (TTR). It is designed to target and
                silence TTR messenger RNA, thereby blocking the production of TTR protein before it is made. ONPATTRO
                blocks the production of TTR in the liver, reducing its accumulation in the body’s tissues in order to
                halt or slow down the progression of the polyneuropathy associated with the disease.
            </p>
            <p class="article-text">
                Over the last fifteen years taiba has earned a reputation as a regional leading company in rare diseases
                and currently represents leading multinational companies pioneer in their fields such as Alnylam,
                Aegerion, Biomarin, Genzyme, Lucane, Veloxis, Vertex etc.
            </p>
        </div>
        <!-- article content end -->

        <!-- sources section -->
        <div class="sources">
            <h3 class="sources-heading">Sources:</h3>
            <a href="https://www.ema.europa.eu/en/medicines/human/EPAR/arikayce-liposomal"
                class="source">https://www.ema.europa.eu/en/medicines/human/EPAR/arikayce-liposomal
            </a>
        </div>
    </section>

    <!-- next post cta section -->
    <div class="next-post">
        <div class="next-post-container">
            <h2 class="next-post-heading">taiba-Elevar Therapeutics <br> cooperation in the Middle East- <br>
                North Africa
                region
            </h2>
            <a href="#" class="next-post-btn">
                Next Post

            </a>
        </div>
    </div>


    <!-- footer -->
    <section class="footer">
        <div class="container-fluid">
            <div class="row bg-image footer-banner">
                <div class="col-lg-12">
                    <img src="../assets/img/healthcarenewlogo.png" alt="" class="healthcarefooter">

                    <a href="#" class="footer-btn">Visit Website</a>
                </div>
            </div>
            <div class="row bg-second">
                <div class="col-lg-9">
                    <img src="../assets/img/home/footer/TAIBA ACCESS RARE FOOTER LOGO_.png" alt="" class="accessrare">
                    <p style="margin-top: 50px;" class="social">FOLLOW US&nbsp;&nbsp;
                        <a href="#"><img src="../assets/img/home/footer/LINKEDIN.png" alt="" class="social-icons"></a>
                        <a href="#"><img src="../assets/img/home/footer/TWITTER_.png" alt="" class="social-icons"></a>
                        <a href="#"><img src="../assets/img/home/footer/FB_.png" alt="" class="social-icons"></a>
                        <a href="#"><img src="../assets/img/home/footer/IG_.png" alt="" class="social-icons"></a>
                    </p>
                    <p class="copyright sheik-desktop" style="font-size:10pt;">Copyright &copy;2021</p>
                    </ul>
                </div>
                <div class="col-lg-3 footer-nav-outer">
                    <div class="footer-nav-container">
                        <img src="../assets/img/home/footer/LINE_.png" alt="" class="footer-line">
                        <ul class="footer-links">
                            <li><a href="./home.html">Who we are</a></li>
                            <li><a href="./patient-support.html">Patient support</a></li>
                            <li><a href="./aof.html">Areas of Focus</a></li>
                            <li><a href="./whatwedo.html">What we do</a></li>
                            <li><a href="./partnerships.html">Partnership</a></li>
                            <li><a href="./news.html">News</a></li>
                            <li><a href="./connect.html">Connect</a></li>
                        </ul>
                    </div>
                    <p class="copyright sheik-mobile">Copyright &copy;2021</p>
                </div>
            </div>
        </div>
    </section>


    <script>
        document.querySelector(".scroll-btn").addEventListener("click", e => {
            window.scrollTo(0, 1000)
        })
    </script>

    <!-- bootstrap js cdn link-->
    <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.0.1/dist/js/bootstrap.bundle.min.js"
        integrity="sha384-gtEjrD/SeCtmISkJkNUaaKMoLD0//ElJ19smozuHV6z3Iehds+3Ulb9Bn9Plx0x4" crossorigin="anonymous">
        </script>

    <!-- jquery cdn link -->
    <script src="https://code.jquery.com/jquery-3.6.0.slim.min.js"
        integrity="sha256-u7e5khyithlIdTpu22PHhENmPcRdFiHRjhAuHcs05RI=" crossorigin="anonymous"></script>


    <script src="./../assets/js/internal-linking.js"></script>

    <script src="./..//assets/js/scroll-up.js"></script>
    <script src="./../assets/js/animate-footer-banner.js"></script>
</body>

</html>